Folio Search · free preview

Papers on “alzheimer disease biomarkers early diagnosis”

Live results from Semantic Scholar, CrossRef and OpenAlex — no account needed to look.

1. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

   Guy M. McKhann, David S. Knopman, Howard Chertkow, et al. · 2011 · Alzheimer s & Dementia · 19,056 cites

   The National Institute on Aging and the Alzheimer's Association charged a workgroup with the task of revising the 1984 criteria for Alzheimer's disease (AD) dementia. The workgroup sought to ensure that the revised criteria would be flexible enough to be used by both general healthcare providers without access to neuropsychological testing, advanced imaging, and cerebrospinal fluid measures, and specialized investigators involved in research or in clinical trial studies who would have these tools available. We present criteria for all-cause dementia and for AD dementia. We retained the general framework of probable AD dementia from the 1984 criteria. On the basis of the past 27 years of expe

2. NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease

   Clifford R. Jack, David A. Bennett, Kaj Blennow, et al. · 2018 · Alzheimer s & Dementia · 10,757 cites

   In 2011, the National Institute on Aging and Alzheimer's Association created separate diagnostic recommendations for the preclinical, mild cognitive impairment, and dementia stages of Alzheimer's disease. Scientific progress in the interim led to an initiative by the National Institute on Aging and Alzheimer's Association to update and unify the 2011 guidelines. This unifying update is labeled a "research framework" because its intended use is for observational and interventional research, not routine clinical care. In the National Institute on Aging and Alzheimer's Association Research Framework, Alzheimer's disease (AD) is defined by its underlying pathologic processes that can be document

3. Lecanemab in Early Alzheimer’s Disease

   Christopher H. van Dyck, Chad J. Swanson, Paul Aisen, et al. · 2022 · New England Journal of Medicine · 5,583 cites

   BACKGROUND: The accumulation of soluble and insoluble aggregated amyloid-beta (Aβ) may initiate or potentiate pathologic processes in Alzheimer's disease. Lecanemab, a humanized IgG1 monoclonal antibody that binds with high affinity to Aβ soluble protofibrils, is being tested in persons with early Alzheimer's disease. METHODS: We conducted an 18-month, multicenter, double-blind, phase 3 trial involving persons 50 to 90 years of age with early Alzheimer's disease (mild cognitive impairment or mild dementia due to Alzheimer's disease) with evidence of amyloid on positron-emission tomography (PET) or by cerebrospinal fluid testing. Participants were randomly assigned in a 1:1 ratio to receive i

4. Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease

   Randall J. Bateman, Chengjie Xiong, Tammie L.S. Benzinger, et al. · 2012 · New England Journal of Medicine · 3,884 cites

   BACKGROUND: The order and magnitude of pathologic processes in Alzheimer's disease are not well understood, partly because the disease develops over many years. Autosomal dominant Alzheimer's disease has a predictable age at onset and provides an opportunity to determine the sequence and magnitude of pathologic changes that culminate in symptomatic disease. METHODS: In this prospective, longitudinal study, we analyzed data from 128 participants who underwent baseline clinical and cognitive assessments, brain imaging, and cerebrospinal fluid (CSF) and blood tests. We used the participant's age at baseline assessment and the parent's age at the onset of symptoms of Alzheimer's disease to calcu

5. The neuropathological diagnosis of Alzheimer’s disease

   Michael DeTure, Dennis W. Dickson · 2019 · Molecular Neurodegeneration · 3,426 cites

   Alzheimer's disease is a progressive neurodegenerative disease most often associated with memory deficits and cognitive decline, although less common clinical presentations are increasingly recognized. The cardinal pathological features of the disease have been known for more than one hundred years, and today the presence of these amyloid plaques and neurofibrillary tangles are still required for a pathological diagnosis. Alzheimer's disease is the most common cause of dementia globally. There remain no effective treatment options for the great majority of patients, and the primary causes of the disease are unknown except in a small number of familial cases driven by genetic mutations. Confo

6. Neuropathological Alterations in Alzheimer Disease

   Alberto Serrano‐Pozo, Matthew P. Frosch, Eliezer Masliah, et al. · 2011 · Cold Spring Harbor Perspectives in Medicine · 3,416 cites

   The neuropathological hallmarks of Alzheimer disease (AD) include "positive" lesions such as amyloid plaques and cerebral amyloid angiopathy, neurofibrillary tangles, and glial responses, and "negative" lesions such as neuronal and synaptic loss. Despite their inherently cross-sectional nature, postmortem studies have enabled the staging of the progression of both amyloid and tangle pathologies, and, consequently, the development of diagnostic criteria that are now used worldwide. In addition, clinicopathological correlation studies have been crucial to generate hypotheses about the pathophysiology of the disease, by establishing that there is a continuum between "normal" aging and AD dement

7. Alzheimer Disease: An Update on Pathobiology and Treatment Strategies

   Justin M. Long, David M. Holtzman · 2019 · Cell · 3,310 cites

8. Donanemab in Early Symptomatic Alzheimer Disease

   John R. Sims, Jennifer A. Zimmer, Cynthia Evans, et al. · 2023 · JAMA · 2,794 cites

   Importance: There are limited efficacious treatments for Alzheimer disease. Objective: To assess efficacy and adverse events of donanemab, an antibody designed to clear brain amyloid plaque. Design, Setting, and Participants: Multicenter (277 medical research centers/hospitals in 8 countries), randomized, double-blind, placebo-controlled, 18-month phase 3 trial that enrolled 1736 participants with early symptomatic Alzheimer disease (mild cognitive impairment/mild dementia) with amyloid and low/medium or high tau pathology based on positron emission tomography imaging from June 2020 to November 2021 (last patient visit for primary outcome in April 2023). Interventions: Participants were rand